medigraphic.com
ISSN 2225-4676 (Electronic)

2015, Number 1

Next >>

Rev Cubana Neurol Neurocir 2015; 5 (1)

Botox in chronic migraine

Fayyaz A

Language: Spanish
References: 20
Page: 1-4
PDF size: 253.52 Kb.


ABSTRACT

Objective: To review the evidence of efficacy of Botox in chronic migraine (CM), its critique and the key findings from prospective data on real life patients.
Development: CM is the most disabling form of migraine that affects around 2% of the general population and has significant impact on the quality of life of an individual with reduced ability to work or perform various activities of daily living. Medication used for prophylaxis of episodic migraine may well work in CM, although only topiramate has the published evidence. Botox was licensed for CM prophylaxis following publication of results of randomized controlled study (PREEMPT). Recently results of a large cohort of real life patients have been published (data from Hull Migraine Clinic, United Kingdom).
Conclusions: Hull Migraine Clinic study provides the first prospective real-life data on patients with CM treated with Botox in a tertiary headache centre. The study suggests a revision for defining a responder. The impact of medication overuse on the response, any predictors for response to treatment, long-term outcome, duration of treatment, development of resistance to Botox and relapse rate after stopping treatment remains unclear.


REFERENCES

  1. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of Chronic Migraine: a systemic review. Cephalalgia. 2010;30:599-609.

  2. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629-808. doi: 10.1177/0333102413485658.

  3. Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, et al. Prevalence of Chronic Migraine and medication overuse headache in Germany-the German DMKG headache study. Cephalalgia. 2010;30:207-13. doi: 10.1111/j.1468-2982.2009.01906.x.

  4. Negro A, Martelletti P. Chronic Migraine plus medication overuse headache: two entities or not? J headache Pain. 2011;12(6):593-601. doi: 10.1007/s10194-011-0388-3.

  5. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301-15. doi: 10.1177/0333102410381145.

  6. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of Chronic Migraine and Episodic Migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428-32. doi: 10.1136/jnnp.2009.192492.

  7. Victor TW, Hu X, Campbell J, White RE, Buse DC, Lipton RB. Association between migraine, anxiety and depression. Cephalalgia. 2010;30:567-75. doi: 10.1111/j.1468-2982.2009.01944.x.

  8. Silberstein, SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170-80.

  9. Deiner HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-23.

  10. Trust TM. Preventive treatments for migraine. 2013 [citado 09.11.2014]. Disponible en: http://www.migrainetrust.org/preventive-treatments

  11. National Institute for Clinical Excellence. Transcranial Magnetic Stimulation for treating and preventing migraine. 2014 [citado 09.11.2014]. Disponible en: http://www.nice.org.uk/guidance/ipg477

  12. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921-36. doi: 10.1111/j.1526-4610.2010.01678.x.

  13. Aurora SK, Winner P, Freeman MC, Speirings EL, Heiring JO, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical programme. Headache. 2011;51:1358-73. doi: 10.1111/j.1526-4610.2011.01990.

  14. Medicine and Healthcare Product Regulatory Agency (MHRA). 2010 [citado 09.11.2014]. Disponible en: www.mhra.gov.uk

  15. US Food and Drug Administration (FDA). 2010 [citado 09.11.2014]. Disponible en: www.fda.gov

  16. National Institute for Health and Care Excellence (NICE). 2012 [citado 09.11.2014]. Disponible en: http://www.nice.org.uk/guidance/ta260

  17. Olesen J, Tfelt-Hansen P. License for Botox in so-called chronic migraine. Lancet. 2010;376:1825-6. doi: 10.1016/S0140-6736(10)62165-4.

  18. Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484-95. doi: 10.1111/j.1468-2982.2008.01555.x.

  19. Ahmed F, Khalil M. Hull Headache Diary. 2013 [citado 09.11.2014]. Disponible en: http://www.bash.org.uk/about/headache-diary

  20. Khalil M, Zafar HW, Quarshie V, Ahmed F. Prospective analysis of the use of OnabotulinumtoxinA (Botox) in the treatment of chronic migraine; real life data in 254 patients from Hull, UK. J Headache Pain. 2014;15:54. doi: 10.1186/1129-2377-15-54.




2020     |     www.medigraphic.com